Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,974 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Normal Pregnancy Clear all

Conditions: Visceral Prolapse
Interventions: Open, Robotic, or Laparoscopic, Transvaginal Native Tissue Repair, Uphold™ LITE; Procedure
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Albuquerque, New Mexico + 6 more

Conditions: Diabetic Kidney Disease
Interventions: Selonsertib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 5
States / cities: Denver, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
Interventions: TRX518, Cyclophosphamide, Avelumab; Drug
Lead sponsor: Leap Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more

Conditions: Systemic Inflammatory Response Syndrome, Acute Kidney Injury
Interventions: coronary artery bypass grafting using cardiopulmonary bypass; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions: Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres; Procedure · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: IgAN, LN, MN, C3G
Interventions: OMS721 (narsoplimab); Biological
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more

Conditions: Normal Renal Function, Impaired Renal Function
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions: INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more

Conditions: Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions: KYV-101, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: David Porter; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer, Small Cell Lung Cancer Extensive Stage
Interventions: Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions: Ambulatory Blood Pressure Measurement; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions: Reltecimod 0.5 mg/kg, Placebo; Drug
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
Interventions: electroacupuncture therapy, sham intervention, quality-of-life assessment; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 5 Years to 35 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions: Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing; Other · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more

Conditions: Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
Interventions: Vorinostat (SAHA), Velcade (PS-341, Bortezomib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
Interventions: intravenous immune globulin (IVIG); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Livingston, New Jersey • New York, New York

Conditions: Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Palo Alto, California • Sacramento, California + 23 more

Conditions: Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions: Metformin, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 13 Years to 25 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Pregnant Individuals Requesting Standard Microarray
Interventions: Genomic Sequencing; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kidney Diseases, Hyponatremia
Interventions: conivaptan hydrochloride; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Renal Cell Carcinoma
Interventions: Anti-Transforming Growth Factor-beta (GC 1008); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Little Brunswick, New Jersey

Conditions: Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Breast Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Breast Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Breast Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine; Drug · Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: cisplatin, paclitaxel, quality-of-life assessment; Drug · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Search by objective public record fields.

Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Platelets as Regulators of Inflammation in Cardiac Surgery

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Preventive IVIG Therapy for Congenital Heart Block

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

Genomic Sequencing in Anatomically Normal Fetuses

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer